GLP-1 Market
LLY $1404.97 ▼ -0.9% NVO $40.45 ▼ -4.1% PFE $30.60 ▼ -0.6% VKTX $25.93 ▼ -7.3% KLRA $12.41 ▼ -3.0% GPCR $19.15 ▼ -5.9% RHHBY $60.95 ▲ +3.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ARO-INHBE

Company
Arrowhead Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 5, 2026

Trial details
  • Completed NCT NCT00100893

    IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

    Not yet reported City of Hope Medical Center 37 participants Est. completion 2013-10 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00566553

    The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women

    Not yet reported Mayo Clinic 39 participants Est. completion 2011-09 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06700538

    A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported Arrowhead Pharmaceuticals 190 participants Est. completion 2028-02-15 15 sites Mixed
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07859813

    A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis

    Not yet reported Arrowhead Pharmaceuticals 252 participants Est. completion 2029-10 Stand-alone
    MASH
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.